Cook SJ - Search Results

1

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.

Caunt CJ, Sale MJ, Smith PD, Cook SJ. Caunt CJ, et al. Among authors: cook sj. Nat Rev Cancer. 2015 Oct;15(10):577-92. doi: 10.1038/nrc4000. Nat Rev Cancer. 2015. PMID: 26399658 Review.

2

Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.

Sunters A, Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, Cook SJ, Burgering BM, Coombes RC, Lam EW. Sunters A, et al. Among authors: cook sj. Cancer Res. 2006 Jan 1;66(1):212-20. doi: 10.1158/0008-5472.CAN-05-1997. Cancer Res. 2006. PMID: 16397234

3

DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5.

Arkell RS, Dickinson RJ, Squires M, Hayat S, Keyse SM, Cook SJ. Arkell RS, et al. Among authors: cook sj. Cell Signal. 2008 May;20(5):836-43. doi: 10.1016/j.cellsig.2007.12.014. Epub 2007 Dec 27. Cell Signal. 2008. PMID: 18280112

4

Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival.

Roderick HL, Cook SJ. Roderick HL, et al. Among authors: cook sj. Nat Rev Cancer. 2008 May;8(5):361-75. doi: 10.1038/nrc2374. Nat Rev Cancer. 2008. PMID: 18432251 Free article. Review.

5

Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.

Wickenden JA, Jin H, Johnson M, Gillings AS, Newson C, Austin M, Chell SD, Balmanno K, Pritchard CA, Cook SJ. Wickenden JA, et al. Among authors: cook sj. Oncogene. 2008 Dec 4;27(57):7150-61. doi: 10.1038/onc.2008.335. Epub 2008 Sep 22. Oncogene. 2008. PMID: 18806830 Free PMC article.

6

Tumour cell survival signalling by the ERK1/2 pathway.

Balmanno K, Cook SJ. Balmanno K, et al. Among authors: cook sj. Cell Death Differ. 2009 Mar;16(3):368-77. doi: 10.1038/cdd.2008.148. Epub 2008 Oct 10. Cell Death Differ. 2009. PMID: 18846109 Review.

7

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.

Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ. Balmanno K, et al. Among authors: cook sj. Int J Cancer. 2009 Nov 15;125(10):2332-41. doi: 10.1002/ijc.24604. Int J Cancer. 2009. PMID: 19637312

8

Down-regulation of Cdx2 in colorectal carcinoma cells by the Raf-MEK-ERK 1/2 pathway.

Krueger F, Madeja Z, Hemberger M, McMahon M, Cook SJ, Gaunt SJ. Krueger F, et al. Among authors: cook sj. Cell Signal. 2009 Dec;21(12):1846-56. doi: 10.1016/j.cellsig.2009.07.020. Epub 2009 Aug 14. Cell Signal. 2009. PMID: 19686845 Free PMC article.

9

Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.

Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA, Smith PD, Cook SJ. Little AS, et al. Among authors: cook sj. Sci Signal. 2011 Mar 29;4(166):ra17. doi: 10.1126/scisignal.2001752. Sci Signal. 2011. Corrected and republished in: Sci Signal. 2011;4(170):er2. doi: 10.1126/scisignal.4170er2 PMID: 21447798 Corrected and republished.

10

A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.

Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA, Smith PD, Cook SJ. Little AS, et al. Among authors: cook sj. Sci Signal. 2011;4(170):er2. doi: 10.1126/scisignal.4170er2. Sci Signal. 2011. PMID: 21674991

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

248 results

Search Page

Filters